Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- Colorectal Cancer
- Interventions
- Biological: bevacizumabDrug: fluorouracilDrug: capecitabineDrug: irinotecan hydrochlorideDrug: leucovorin calcium
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Southern Italy Cooperative Oncology Group
- Target Recruit Count
- 672
- Registration Number
- NCT00797485
- Locations
- 🇮🇹
Southern Italy Cooperative Oncology Group, Naples, Italy
Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 48
- Registration Number
- NCT00786643
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
- Conditions
- Uterine Neoplasms
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 11
- Registration Number
- NCT00782041
- Locations
- 🇹🇭
Sanofi aventis administrative office, Bangkok, Thailand
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT00778102
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
- Conditions
- Colorectal CancerPrimary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 264
- Registration Number
- NCT00769405
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷Institut Curie, Paris, France
🇫🇷Hopital de l'Archet CHU de Nice, Nice, France
Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- University of Toyama
- Target Recruit Count
- 160
- Registration Number
- NCT00766480
- Locations
- 🇯🇵
Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
🇯🇵Kagoshima University, Kagoshima, Japan
🇯🇵Aichi Cancer Center, Nagoya, Aichi, Japan
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
- Conditions
- Primary Peritoneal Cavity CancerColorectal Cancer
- Interventions
- Biological: cetuximabDrug: fluorouracilDrug: leucovorin calciumDrug: oxaliplatinProcedure: adjuvant therapyProcedure: therapeutic conventional surgery
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 18
- Registration Number
- NCT00766142
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer
- Conditions
- Esophageal Cancer
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2008-09-26
- Lead Sponsor
- CONKO-Studiengruppe
- Target Recruit Count
- 92
- Registration Number
- NCT00759226
- Locations
- 🇩🇪
Charite Universitätsmedizin Berlin, Berlin, Germany
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 24
- Registration Number
- NCT00755118
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Cancer Research UK, Glasgow
- Target Recruit Count
- 6088
- Registration Number
- NCT00749450
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.